Zobrazeno 1 - 10
of 887
pro vyhledávání: '"elbasvir"'
Autor:
Jean‐Pierre Bronowicki, Patrick Miailhes, Bertrand Hanslik, Denis Ouzan, Dominique Larrey, Ghassan Riachi, Régine Truchi, Vincent Jouannaud, Dan Pospait, Armand Abergel, Xavier Causse, Stéphanie Perot, Jérémy Skrzypski, Astrid De Hautecloque, Axelle Spampinato, Philippe Mariot, Philippe Sogni, the Zephyr Study group
Publikováno v:
Health Science Reports, Vol 6, Iss 1, Pp n/a-n/a (2023)
Abstract Background and Aim The efficacy and safety profiles of elbasvir–grazoprevir (EBR/GZR) has been established in more than 10 clinical trials. However, the characteristics of patients treated in routine clinical practice may differ. The prese
Externí odkaz:
https://doaj.org/article/ee9c3ea9dabe43cda866ce4d40cbfb40
Autor:
Ahmad AlEid, Areej Al Balkhi, Adel Qutub, Shahem Abbarh, Abed AlLehibi, Abdullah Almtawa, Nawwaf Al Otaibi, Ahmed AlGhamdi, Adel AlGhamdi, Abdulrahman Alamr, Shameem Ahmad, Khalid Al Sayari, Bashaar Al Ibrahim, Abdullah AlKhathlan
Publikováno v:
The Saudi Journal of Gastroenterology, Vol 28, Iss 3, Pp 225-232 (2022)
Background: Cost, adverse events, and long treatment duration can be significant obstacles in treating hepatitis C virus (HCV)-infected individuals. Shortening the treatment regimen can minimize these barriers, thereby enhancing adherence and increas
Externí odkaz:
https://doaj.org/article/00e74c12f7984cbeacf30facf4566a56
Autor:
Bayu Laksono, Nenny Agustanti, Rudi Supriyadi, Muhammad Begawan Bestari, Siti Aminah Abdurachman
Publikováno v:
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy, Vol 22, Iss 1, Pp 21-28 (2021)
Background: Approximately 5-60% of hemodialysis patients have comorbid of hepatitis C virus (HCV) infection. The survival rate of hemodialysis patients HCV is lower than those without HCV due to the risk of liver fibrosis and cardiovascular disease.
Externí odkaz:
https://doaj.org/article/21b8726d90ca4bad8ba93547c827e39c
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
ObjectiveThis study aims to systematically review recent economic evaluations of elbasvir/grazoprevir (EBR/GZR) for chronic hepatitis C (CHC), to critically appraise the reporting quality and to summarize the results.MethodsA literature search was un
Externí odkaz:
https://doaj.org/article/bd95293d7c414096b3c1d20355ef0b5a
Publikováno v:
Clinical Case Reports, Vol 10, Iss 3, Pp n/a-n/a (2022)
Abstract Extrahepatic manifestations of chronic hepatitis C virus (HCV) infection frequently involve the skin. Here, we report the case of a woman, who experienced a psoriasis exacerbation on DAA treatment, which lead to psoriasis resolution upon HCV
Externí odkaz:
https://doaj.org/article/8b2c48f8ae2d47788f3c78aff759eaae
Publikováno v:
Journal of the Formosan Medical Association, Vol 119, Iss 5, Pp 933-940 (2020)
Background/Purpose: The assessment of drug–drug interaction (DDI) is important not only for safety but also for maintaining the efficacy of direct acting antivirals in chronic hepatitis C (CHC). This study aims to evaluate DDI before and during elb
Externí odkaz:
https://doaj.org/article/18093c28cc9a41b09ed20d122f1fb5df
Autor:
Li H, Yang Z, Zhang S, Xu L, Wei Y, Jiang J, Caro L, Feng HP, McCrea JB, Li M, Xie S, Wang J, Zhao XM, Mu S
Publikováno v:
Clinical Pharmacology: Advances and Applications, Vol Volume 12, Pp 1-11 (2020)
Haiyan Li,1 Zhenhua Yang,1 Shuang Zhang,1 Lin Xu,1 Yudong Wei,1 Jun Jiang,2 Luzelena Caro,3 Hwa-Ping Feng,3 Jacqueline B McCrea,3 Meng Li,2 Shuang Xie,2 Jiangdian Wang,2 Xu Min Zhao,2 Shengmei Mu2 1Drug Clinical Trial Center, Peking University Third
Externí odkaz:
https://doaj.org/article/5ba2d1b73d934369bcea130b373ff7f2
Publikováno v:
Renal Failure, Vol 42, Iss 1, Pp 377-380 (2020)
Hepatitis C virus (HCV) infection is known to affect long-term patient survivals. Elbasvir/grazoprevir (EBR/GZR) has shown a high cure rate in hemodialysis patients with HCV infection. However, the combination is rarely used in peritoneal dialysis pa
Externí odkaz:
https://doaj.org/article/5536673cf5654df4b1615abce1c4db19
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Objectives: Baseline presence of nonstructural protein 5A (NS5A) resistance-associated variants can attenuate the efficacy of new direct-acting antivirals. A potential method to attain the higher efficacy would be to screen for NS5A polymorphisms pri
Externí odkaz:
https://doaj.org/article/241759756a7641e8bb76108b2c22c0ef
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.